Insider and congress filings

Becton, Dickinson and Company (BDX)

NYSE · Healthcare · 371 insider transactions · 133 congress trades · last filed 26 days agoS&P 500

19
Open-market insider filings shown
1d
Median delay on the insider filings, in business days
within the two business day rule
0 buys·19 sells
Purchases and sales in the filings shown
Get a push when an insider at Becton, Dickinson and Company trades.

Free on iOS and Android.

About Becton, Dickinson and Company

from the company's filings and listing, as of Oct 24, 2026
Exchange
NYSE
Sector
Healthcare
Industry
Medical - Instruments & Supplies
Chief executive
Thomas E. Polen Jr.
Employees
72,000
Listed since
-
Market value
$54.2B
Price to earnings (12 mo)
59.9
Net income per share, as reported (12 mo)
$3.42
Dividend yield
2.00%

www.bd.com

Earnings

6 reported quarters · next on Nov 5, 2026
QuarterEPSEPS expectedRevenueRevenue expectedResult
Q3 FY2026reported Aug 6, 2026$3.23$3.14$5.0B$4.9BEPS beatRevenue beat
Q2 FY2026reported May 7, 2026$2.90$2.78$4.7B$4.7BEPS beatRevenue in line
Q1 FY2026reported Feb 9, 2026$2.91$2.21$4.5B$5.1BEPS beatRevenue miss
Q4 FY2025reported Nov 6, 2025$3.96$3.92$5.9B$5.9BEPS in lineRevenue in line
Q3 FY2025reported Aug 7, 2025$3.68$3.40$5.5B$5.5BEPS beatRevenue in line
Q2 FY2025reported May 1, 2025$3.35$3.28$5.3B$5.4BEPS beatRevenue miss

Actual against the consensus estimate at the time. A flag marks a beat or a miss of more than 1.5% either way; inside that band the quarter is in line. A flag reads n/a only when a number is missing. Quarterly EPS is the figure set against the consensus, usually adjusted, so the quarters need not add up to the 12-month net income per share above. An estimate is a forecast made by analysts, not a company target.

Executive pay

as filed for fiscal 2025 · proxy filed Dec 18, 2025
ExecutiveSalaryStock awardsOtherTotal
Thomas E. PolenChairman, Chief Executive Officer and President$1.4M$10.0M$5.7M$17.1M
Christopher J. DelOreficeExecutive Vice President and Chief Financial Officer$838K$3.1M$1.9M$5.9M
Michael C. FeldExecutive Vice President, Chief Revenue Officer and President, Life Sciences Segment$775K$1.6M$1.7M$4.1M
Michael D. GarrisonExecutive Vice President and President, Medical Essentials and BioPharma Systems Segments$769K$1.6M$1.2M$3.6M
Richard E. ByrdExecutive Vice President and President, Interventional Segment$756K$1.4M$1.2M$3.4M

The summary compensation table from the proxy statement for fiscal 2025, with titles as filed then. Executives who have since left are not shown. Read the filing

Institutional holders

13F positions as of Jun 30, 2026
HolderValueSharesShares vs prior qtr% of shares out
BlackRock, Inc.$3.7B24,592,166-6.0%8.95%
Vanguard Capital Management LLC$2.7B17,987,834-2.7%6.55%
Massachusetts Financial Services Co$2.5B8,650,967-4.9%3.15%
State Street Corp$2.3B15,000,064+8.5%5.46%
Vanguard Portfolio Management LLC$2.3B14,974,136-2.2%5.45%
First Eagle Investment Management, LLC$2.1B13,815,335+15.8%5.03%
Invesco Ltd.$1.3B8,898,488-12.5%3.24%
Geode Capital Management, LLC$1.2B8,141,586+14.6%2.96%
Franklin Templeton Inc$1.1B7,011,592+30.7%2.55%
Wellington Management Group LLP$962.2M6,357,986-3.9%2.31%
Greenhaven Associates Inc$859.8M5,681,708New2.07%
Norges Bank$631.0M4,169,523New1.52%

A 13F reports long US equity positions and is filed within 45 days of the quarter end, so these are positions as they stood on Jun 30, 2026. New: not in this holder's prior 13F as reported; a change of filer ID can also show as new. For a manager's whole book see the fund directory. What a 13F covers and leaves out is explained in our guide to Form 13F.

Know when the next BDX filing is reported.

GetSignal watches Form 4 and STOCK Act filings and pushes each one to your phone as it is published, with the history behind it. Free on iOS and Android.

Open-market insider trades

19 filings shown · newest filing first
InsiderActionSharesPriceValueTrade dateDelay
(business days)
Michael FeldEVP, Chief Revenue OfficerSold · scheduled76$183.70$14KSep 28, 2026filed Sep 29, 20261d
Michael FeldEVP, Chief Revenue OfficerSold · scheduled165$188.49$31KAug 26, 2026filed Aug 27, 20261d
Thomas E. Polen Jr.Chairman, CEO and PresidentSold · scheduled4,152$185.00$768KAug 13, 2026filed Aug 14, 20261d
Roland GoetteEVP and President, EMEASold2,438$180.84$441KAug 11, 2026filed Aug 12, 20261d
Michael FeldEVP, Chief Revenue OfficerSold · scheduled75$157.13$12KJul 27, 2026filed Jul 28, 20261d
Michael FeldEVP, Chief Revenue OfficerSold · scheduled75$152.80$11KJun 26, 2026filed Jun 26, 20260d
Michael David GarrisonEVP & Pres Med.essntl&BiopharmSold · scheduled1,100$145.66$160KJun 24, 2026filed Jun 25, 20261d
Michael David GarrisonEVP & Pres Med.essntl&BiopharmSold · scheduled1,100$151.48$167KJun 10, 2026filed Jun 11, 20261d
Thomas E. Polen Jr.Chairman, CEO and PresidentSold · scheduled2,764$146.35$405KJun 1, 2026filed Jun 3, 20262d
Michael FeldEVP, Chief Revenue OfficerSold · scheduled75$147.35$11KMay 26, 2026filed May 27, 20261d
Michael FeldEVP, Chief Revenue OfficerSold · scheduled74$151.94$11KApr 27, 2026filed Apr 28, 20261d
Michael FeldEVP, Chief Revenue OfficerSold · scheduled75$156.83$12KMar 26, 2026filed Mar 27, 20261d
Michael FeldEVP, Chief Revenue OfficerSold · scheduled75$181.84$14KFeb 26, 2026filed Feb 27, 20261d
Bertram L. ScottDirectorSold953$182.61$174KFeb 18, 2026filed Feb 18, 20260d
Michael FeldEVP, CRO & Pres. Life SciencesSold · scheduled75$202.73$15KJan 26, 2026filed Jan 28, 20262d
Michael David GarrisonEVP & Pres Med.essntl&BiopharmSold · scheduled · 2 lines1,610$207.46$334KJan 15, 2026filed Jan 16, 20261d
Michael FeldEVP, CRO & Pres. Life SciencesSold · scheduled74$196.08$15KDec 26, 2025filed Dec 29, 20251d
Michael David GarrisonEVP & Pres Med.essntl&BiopharmSold · scheduled629$196.03$123KDec 17, 2025filed Dec 17, 20250d
Michael FeldEVP, CRO & Pres. Life SciencesSold · scheduled75$193.36$15KDec 1, 2025filed Dec 2, 20251d

One row is one filing, newest filing first. A filing that reported its trade in several tranches is summed, priced at the weighted average, and marked with its line count. Scheduled: set up in advance under a Rule 10b5-1 trading plan. The delay counts business days from the trade to the filing, the unit of Form 4's two business day deadline: weekends and federal holidays are skipped. How the filing itself works is explained in our guide to Form 4.

Other Form 4 activity (20)
InsiderEventSharesDate
Vitor RoqueEVP & Chief Financial OfficerTax withholding190Sep 2, 2026
Michael FeldEVP, Chief Revenue OfficerTax withholding1,049Aug 20, 2026
Thomas E. Polen Jr.Chairman, CEO and PresidentDisposed to issuer39,126Aug 13, 2026
Thomas E. Polen Jr.Chairman, CEO and PresidentOption exercise43,278Aug 13, 2026
Carrie L. ByingtonDirectorStock award94Aug 6, 2026
Robert Luther HuffinesDirectorStock award189Aug 6, 2026
Bilal MuhsinEVP & President Connected CareTax withholding1,935Jul 2, 2026
Bilal MuhsinEVP & President Connected CareStock award14,342Jul 1, 2026
Manish SinhaEVP and Chief People OfficerOther Form 4 entry (see filing)2,663Nov 26, 2025
Manish SinhaEVP and Chief People OfficerOther Form 4 entry (see filing)3,147Nov 26, 2024
Manish SinhaEVP and Chief People OfficerOther Form 4 entry (see filing)3,408Nov 26, 2023
Manish SinhaEVP and Chief People OfficerOther Form 4 entry (see filing)3,555Nov 26, 2022
Manish SinhaEVP and Chief People OfficerOther Form 4 entry (see filing)5,690Nov 26, 2021
Manish SinhaEVP and Chief People OfficerOther Form 4 entry (see filing)4,441Nov 26, 2020
Manish SinhaEVP and Chief People OfficerOther Form 4 entry (see filing)4,100Nov 26, 2019
Manish SinhaEVP and Chief People OfficerOther Form 4 entry (see filing)4,174Nov 26, 2018
Thomas E. Polen Jr.Chairman, CEO and PresidentDisposed to issuer17,445Jun 1, 2026
Thomas E. Polen Jr.Chairman, CEO and PresidentOption exercise20,209Jun 1, 2026
Peter MenziusoEVP and President, BDIStock award14,258Jun 1, 2026
Vitor RoqueEVP & Chief Financial OfficerStock award1,721May 7, 2026

Awards, option exercises, shares withheld to cover tax and gifts all file on the same form as a purchase or a sale. None of them is a decision to trade, so they sit here rather than beside the ones that are.

Congress trades in BDX

20 disclosures of 133 on record · median 28d of the 45 allowed

Since the trade: the stock's move from the trade date to the latest close we hold (figures as of Oct 25, 2026), not the member's result. Not investment advice.

MemberTypeActionAmount disclosedStock since the tradeTrade dateDisclosedDelay
Alan ArmstrongSelfStockPurchase$1,001 - $15,000+28.7%S&P 500 +19.8% · +8.9 pts vs S&P 500Mar 27, 2026Jul 21, 2026116d
Ro KhannaStockSale$1,001 - $15,000+37.7%After the saleS&P 500 +0.1% · +37.7 pts vs S&P 500Jun 2, 2026Jul 6, 202634d
Thomas H. Kean, Jr.StockSale$1,001 - $15,000+36.0%After the saleS&P 500 +2.3% · +33.7 pts vs S&P 500May 21, 2026Jun 18, 202628d
Ro KhannaStockSale$1,001 - $15,000+33.2%After the saleS&P 500 +5.4% · +27.8 pts vs S&P 500May 1, 2026Jun 9, 202639d
Ro KhannaStockPurchase$1,001 - $15,000+38.6%S&P 500 +2.8% · +35.8 pts vs S&P 500May 15, 2026Jun 9, 202625d
Ro KhannaStockPurchase$1,001 - $15,000+35.1%S&P 500 +1.3% · +33.8 pts vs S&P 500May 27, 2026Jun 9, 202613d
Ro KhannaStockSale$15,001 - $50,000+28.0%After the saleS&P 500 +10.8% · +17.2 pts vs S&P 500Apr 13, 2026May 11, 202628d
Ro KhannaStockSale$1,001 - $15,000+30.7%After the saleS&P 500 +6.4% · +24.3 pts vs S&P 500Apr 24, 2026May 11, 202617d
Ro KhannaStockPurchase$1,001 - $15,000+27.3%S&P 500 +15.6% · +11.7 pts vs S&P 500Mar 23, 2026Apr 7, 202615d
Kevin HernJointStockSale$15,001 - $50,000+23.1%After the saleS&P 500 +13.2% · +9.8 pts vs S&P 500Mar 17, 2026Apr 3, 202617d
Ro KhannaStockPurchase$1,001 - $15,000-1.4%S&P 500 +10.2% · -11.6 pts vs S&P 500Jan 23, 2026Feb 6, 202614d
Ro KhannaStockPurchase$15,001 - $50,000-1.1%S&P 500 +9.5% · -10.5 pts vs S&P 500Jan 29, 2026Feb 6, 20268d
Ro KhannaStockSale$1,001 - $15,000+12.2%After the saleS&P 500 +11.2% · +1.0 pts vs S&P 500Nov 3, 2025Dec 8, 202535d
Ro KhannaStockSale$1,001 - $15,000+9.5%After the saleS&P 500 +11.5% · -2.0 pts vs S&P 500Nov 10, 2025Dec 8, 202528d
Ro KhannaStockPurchase$1,001 - $15,000+8.1%S&P 500 +14.5% · -6.4 pts vs S&P 500Sep 29, 2025Oct 3, 20254d
Ro KhannaStockPurchase$1,001 - $15,000+11.2%S&P 500 +20.4% · -9.2 pts vs S&P 500Aug 4, 2025Sep 9, 202536d
Lisa C. McClainSpouseStockPurchase$1,001 - $15,000+17.1%S&P 500 +27.2% · -10.1 pts vs S&P 500Jun 17, 2025Aug 13, 202557d
Lisa C. McClainSpouseStockSale$1,001 - $15,000+15.9%After the saleS&P 500 +24.9% · -8.9 pts vs S&P 500Jun 24, 2025Aug 13, 202550d
Thomas H. Kean, Jr.StockPurchase$1,001 - $15,000+13.4%S&P 500 +29.5% · -16.1 pts vs S&P 500May 13, 2025Jun 17, 202535d
Ro KhannaStockPurchase$1,001 - $15,000+12.4%S&P 500 +27.8% · -15.4 pts vs S&P 500May 19, 2025Jun 10, 202522d

Since the trade is an estimate, set beside the S&P 500 over the same window, with the gap between the two in percentage points. The filing carries a band, not a fill, and a sale keeps the stock's sign, so a positive figure after a sale means the stock kept rising after it. An option row carries the underlying stock's move. A row marked n/a is one we hold no figure for.

A delay above 45 days is the gap between the dates on the report; we mark a filing late only after checking it.

Every Congress trade in BDX, filterable by party, chamber, type and account.

Members of Congress reporting a position

6 members · estimate, as of Oct 23, 2026

6 members report a position (estimated). The largest estimated position is in the $50,001 - $100,000 band.

MemberParty, chamberEstimated positionShare of their portfolio
Tom ColeRepublican · House$50,001 - $100,0009.6%
Debbie DingellDemocrat · House$15,001 - $50,0000.4%
Jacky RosenDemocrat · Senate$15,001 - $50,0000.5%
Thomas H. Kean, Jr.Republican · House$15,001 - $50,0000.5%
Gilbert Ray Cisneros, Jr.Democrat · House$1,001 - $15,000<0.1%
Lucy McBathDemocrat · House$1,001 - $15,0000.1%

Estimate, as of Oct 23, 2026. Each position is modelled from the member's disclosed transactions and annual filings: the midpoint of each disclosed band, moved with the stock's price since the trade. It is a rough estimate of a reported position, not a figure from a filing, which is why it is shown as a band. Share of portfolio sets that estimate against the member's whole estimated public-stock portfolio.

Questions

Are insiders buying or selling BDX?

Across the 19 most recent open-market filings shown here, 0 were purchases and 19 were sales. 17 were scheduled in advance under a Rule 10b5-1 plan.

Which members of Congress have traded BDX?

Alan Armstrong, Ro Khanna, Thomas H. Kean, Jr., Kevin Hern and Lisa C. McClain disclosed BDX transactions in the filings shown here.

Which members of Congress hold BDX?

6 members of Congress report a position in BDX in the estimate we hold as of Oct 23, 2026. The largest estimated position belongs to Tom Cole; the next largest, in the $15,001 - $50,000 band, include Debbie Dingell and Jacky Rosen. The estimate is built from disclosed transactions and annual filings, so it is shown as a band rather than a figure from a filing.

Is BDX in the S&P 500 or the Nasdaq 100?

Becton, Dickinson and Company is a current member of the S&P 500, per the membership list we hold as of Oct 26, 2026. Current members of either index get a page here whatever their filing history.

How quickly are BDX trades disclosed?

Insider filings on this page reached the public a median of 1 business day after the transaction (weekends and federal holidays skipped), against the two business days Form 4 allows. Congressional disclosures took a median of 28 days, against the 45 the STOCK Act allows.

How to read a Form 4

A DECISION THE INSIDER MADE

POpen-market purchase. Bought with their own money at the market price.
SOpen-market sale. Sold on the market. A sale marked scheduled was set up in advance under a Rule 10b5-1 plan, often months before.

COMPENSATION PLUMBING

AStock award. Granted as pay, not bought.
MOption exercise. Converting options already held into shares.
FTax withholding. Shares handed back to the company to pay the tax on a grant.
GGift. Given away, with no money changing hands.

Congress rows disclose a value range rather than an exact amount, and the STOCK Act allows up to 45 days to report. Full sourcing and the limits of this data are on the methodology page. A filing is a record of a transaction, not a signal, and nothing here is investment advice.

Data as of Oct 26, 2026.

Related companies

traded by the same members

See every company we track